These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21997489)

  • 1. Abacavir and myocardial infarctions: the benefit of doubt?
    Behrens GM
    AIDS; 2011 Oct; 25(16):2043-5. PubMed ID: 21997489
    [No Abstract]   [Full Text] [Related]  

  • 2. Abacavir and increased risk of myocardial infarction.
    Post FA; Campbell LJ
    Lancet; 2008 Sep; 372(9641):803; author reply 804-5. PubMed ID: 18774412
    [No Abstract]   [Full Text] [Related]  

  • 3. Abacavir and cardiovascular risk: reviewing the evidence.
    Costagliola D; Lang S; Mary-Krause M; Boccara F
    Curr HIV/AIDS Rep; 2010 Aug; 7(3):127-33. PubMed ID: 20521126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies.
    Dorjee K; Choden T; Baxi SM; Steinmaus C; Reingold AL
    Int J Antimicrob Agents; 2018 Nov; 52(5):541-553. PubMed ID: 30040992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abacavir and cardiovascular risk in HIV-infected patients: does T lymphocyte hyperactivation exert a pathogenic role?
    Marchetti G; Casana M; Tincati C; Bellistrì GM; Monforte Ad
    Clin Infect Dis; 2008 Dec; 47(11):1495-6. PubMed ID: 18986270
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparing implications of cardiovascular risk of abacavir and integrase inhibitors: why scientific community is confused and timid?
    Guaraldi G; Milic J
    AIDS; 2023 May; 37(6):1005-1008. PubMed ID: 37017023
    [No Abstract]   [Full Text] [Related]  

  • 7. Abacavir and the potential risk of myocardial infarction.
    Cutrell A; Brothers C; Yeo J; Hernandez J; Lapierre D
    Lancet; 2008 Apr; 371(9622):1413. PubMed ID: 18387668
    [No Abstract]   [Full Text] [Related]  

  • 8. Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study.
    De Luca A; de Gaetano Donati K; Cozzi-Lepri A; Colafigli M; De Curtis A; Capobianchi MR; Antinori A; Giacometti A; Magnani G; Vullo V; Cauda R; Iacoviello L; d'Arminio Monforte A;
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):e98-101. PubMed ID: 22728753
    [No Abstract]   [Full Text] [Related]  

  • 9. Vertigo and abacavir.
    Fantry LE; Staecker H
    AIDS Patient Care STDS; 2002 Jan; 16(1):5-7. PubMed ID: 11839213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
    Pammi M; Arumainayagam J; Kumari B; Ahmed-Jushuf I; Carlin EM; Chandramani S; Riddell L; Ghanem M; Das S
    Int J Clin Pract; 2013 Sep; 67(9):922-3. PubMed ID: 23952469
    [No Abstract]   [Full Text] [Related]  

  • 11. Abacavir and increased risk of myocardial infarction.
    Goicoechea M; McCutchan A
    Lancet; 2008 Sep; 372(9641):803-4; author reply 804-5. PubMed ID: 18774413
    [No Abstract]   [Full Text] [Related]  

  • 12. Warning against rechallenge with abacavir.
    AIDS Patient Care STDS; 1998 Mar; 12(3):229. PubMed ID: 11361938
    [No Abstract]   [Full Text] [Related]  

  • 13. Heart attack risk with abacavir and didanosine.
    AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
    [No Abstract]   [Full Text] [Related]  

  • 14. Large lymphadenopathies complicating the abacavir hypersensitivity reaction.
    García JT; González PR; Hernández-Mora MG; Novoa SR; Quintana FB; Lahoz JG; Vázquez VS
    AIDS; 2007 Oct; 21(16):2254-6. PubMed ID: 18090059
    [No Abstract]   [Full Text] [Related]  

  • 15. CROI 2009: a few key presentations on antiretroviral therapy.
    Gallant JE
    AIDS Read; 2009 Apr; 19(4):129-30, C3. PubMed ID: 19388179
    [No Abstract]   [Full Text] [Related]  

  • 16. Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient.
    de la Rosa R; Harris M; Uyeda L; Goodison K; Keown P; Montaner JS
    AIDS; 2004 Feb; 18(3):578-9. PubMed ID: 15090818
    [No Abstract]   [Full Text] [Related]  

  • 17. Abacavir-induced liver toxicity in an HIV-infected patient.
    Di Filippo E; Ripamonti D; Rizzi M
    AIDS; 2014 Feb; 28(4):613. PubMed ID: 24469001
    [No Abstract]   [Full Text] [Related]  

  • 18. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abacavir and CVD--again.
    Sax PE
    J Watch AIDS Clin Care; 2009 Oct; 21(10):81. PubMed ID: 20458812
    [No Abstract]   [Full Text] [Related]  

  • 19. More on abacavir-induced neuropsychiatric reactions.
    Foster R; Taylor C; Everall IP
    AIDS; 2004 Dec; 18(18):2449. PubMed ID: 15622330
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient.
    El-Sahly HM
    AIDS; 2004 Jan; 18(2):359-60. PubMed ID: 15075569
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.